This Article Figures Only Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Google Scholar Articles by Gladding, P. Articles by Webster, M. PubMed Articles by Gladding, P. Articles by Webster, M. Related Collections Related Article

Pharmacogenetic Testing for Clopidogrel Using the Rapid INFINITI Analyzer

A Dose-Escalation Study

Patrick Gladding, MBChB^_*,,_*, Harvey White, MBChB, DSc^_*, Jamie Voss, MBChB^_*, John Ormiston, MBChB^_*, Jim Stewart, MBChB^_*, Peter Ruygrok, MD, MBChB^_*, Badi Bvaldivia, Ruth Baak, PhD, Catherine White, MBChB^_*, Mark Webster, MBChB^_*

^_* Green Lane Cardiovascular Service, Auckland City Hospital, Auckland, New Zealand
AutoGenomics, Carlsbad, California
Theranostics Lab (NZ) Ltd., Auckland, New Zealand

^_* Reprint requests and correspondence: Dr. Patrick Gladding, Auckland City Hospital, Green Lane Cardiovascular Service, Park Road, Grafton, Auckland, North Island 1061, Auckland, New Zealand (Email: patrickg{at}theranostics.co.nz).

Objectives: Our aim was to assess whether a higher clopidogrel maintenance dose has a greater antiplatelet effect in CYP2C19*2 allele carriers compared with noncarriers.

Background: Clopidogrel is a prodrug that is biotransformed by the cytochrome P450 enzymes CYP2C19, 2C9, and 3A4, 2B6, 1A2. The CYPC219*2 loss of function variant has been associated with a reduced antiplatelet response to clopidogrel and a 3-fold risk of stent thrombosis.

Methods: Forty patients on standard maintenance dosage clopidogrel (75 mg), for 9.4 ± 9.2 weeks, were enrolled into a dose escalation study. Platelet function was assessed at baseline and after 1 week of 150 mg once daily using the VerifyNow platelet function analyzer (Accumetrics Ltd., San Diego, California). Genomic DNA was hybridized to a BioFilmChip microarray on the INFINITI analyzer (AutoGenomics Inc., Carlsbad, California) and analyzed for the CYP19*2, *4, *17, and CYP2C9*2, *3 polymorphisms.

Results: Platelet inhibition increased over 1 week, mean +8.6 ± 13.5% (p = 0.0003). Carriers of the CYP2C19*2 allele had significantly reduced platelet inhibition at baseline (median 18%, range 0% to 72%) compared with wildtype (wt) (median 59%, range 11% to 95%, p = 0.01) and at 1 week (p = 0.03). CYP2C19*2 allele carriers had an increase in platelet inhibition of (mean +9 ± 11%, p = 0.03) and reduction in platelet reactivity (mean –26 ± 38 platelet response unit, p = 0.04) with a higher dose. Together CYP2C19*2 and CYP2C9*3 loss of function carriers had a greater change in platelet inhibition with 150 mg daily than wt/wt (+10.9% vs. +0.7%, p = 0.04).

Conclusions: Increasing the dose of clopidogrel in patients with nonresponder polymorphisms can increase antiplatelet response. Personalizing clopidogrel dosing using pharmacogenomics may be an effective method of optimizing treatment.

Key Words: clopidogrel • pharmacogenetics • personalized • platelets

Abbreviations and Acronyms   CI = confidence interval   PPI = proton pump inhibitor   PRU = platelet response unit

Related Article

The Worry About Clopidogrel "Nonresponsiveness": Identification and Treatment in the Post-Percutaneous Coronary Intervention Patient

Paul A. Gurbel, Udaya S. Tantry, and Alan R. Shuldiner
J. Am. Coll. Cardiol. Intv. 2009 2: 1102-1104. [Full Text] [PDF]

This article has been cited by other articles:

				P. A. Gurbel, U. S. Tantry, and A. R. Shuldiner The Worry About Clopidogrel "Nonresponsiveness": Identification and Treatment in the Post-Percutaneous Coronary Intervention Patient J. Am. Coll. Cardiol. Intv., November 1, 2009; 2(11): 1102 - 1104. [Full Text] [PDF]